SpringWorks Therapeutics Inc (SWTX)
44.86
+0.09
(+0.20%)
USD |
NASDAQ |
May 17, 16:00
44.86
0.00 (0.00%)
After-Hours: 20:00
SpringWorks Therapeutics Revenue (Quarterly): 21.01M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.01M |
| December 31, 2023 | 5.447M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 |
| Date | Value |
|---|---|
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 35.00M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.447M
Minimum
Dec 2023
35.00M
Maximum
Dec 2020
20.48M
Average
21.01M
Median
Mar 2024
Revenue (Quarterly) Benchmarks
| Geron Corp | 0.304M |
| Verastem Inc | -- |
| Karyopharm Therapeutics Inc | 33.13M |
| Syndax Pharmaceuticals Inc | -- |
| Arvinas Inc | 25.30M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -87.38M |
| Total Expenses (Quarterly) | 114.94M |
| EPS Diluted (Quarterly) | -1.18 |
| Enterprise Value | 2.880B |
| Gross Profit Margin (Quarterly) | 94.28% |
| Profit Margin (Quarterly) | -416.0% |
| Earnings Yield | -11.48% |
| Normalized Earnings Yield | -11.48 |